ATE170747T1 - Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz - Google Patents

Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz

Info

Publication number
ATE170747T1
ATE170747T1 AT93900327T AT93900327T ATE170747T1 AT E170747 T1 ATE170747 T1 AT E170747T1 AT 93900327 T AT93900327 T AT 93900327T AT 93900327 T AT93900327 T AT 93900327T AT E170747 T1 ATE170747 T1 AT E170747T1
Authority
AT
Austria
Prior art keywords
treatment
urinary incontinence
antagonists
producing
medicinal product
Prior art date
Application number
AT93900327T
Other languages
English (en)
Inventor
Gareth John Sanger
Kay Alison Wardle
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919127184A external-priority patent/GB9127184D0/en
Priority claimed from GB919127185A external-priority patent/GB9127185D0/en
Priority claimed from GB929219354A external-priority patent/GB9219354D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE170747T1 publication Critical patent/ATE170747T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT93900327T 1991-12-21 1992-12-21 Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz ATE170747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919127184A GB9127184D0 (en) 1991-12-21 1991-12-21 Pharmaceuticals
GB919127185A GB9127185D0 (en) 1991-12-21 1991-12-21 Pharmaceuticals
GB929219354A GB9219354D0 (en) 1992-09-12 1992-09-12 Pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE170747T1 true ATE170747T1 (de) 1998-09-15

Family

ID=27265978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900327T ATE170747T1 (de) 1991-12-21 1992-12-21 Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz

Country Status (9)

Country Link
EP (1) EP0617620B1 (de)
JP (1) JPH07502528A (de)
AT (1) ATE170747T1 (de)
AU (1) AU671430B2 (de)
CA (1) CA2126354C (de)
DE (1) DE69226961T2 (de)
DK (1) DK0617620T3 (de)
ES (1) ES2121984T3 (de)
WO (1) WO1993012785A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
EP0664794A1 (de) * 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl-carbonsäure ester/amide von kondensierten ring-systemen als 5-ht4-rezeptor antagonisten
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
KR19990022096A (ko) * 1995-05-31 1999-03-25 쇼다 오사무 모노시클릭 아미노기를 갖는 인다졸 유도체
IL140118A0 (en) 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
HK1040059A1 (zh) * 1998-06-15 2002-05-24 塞普拉科有限公司 光学纯度(-)-降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
EP1551394A1 (de) * 2002-08-14 2005-07-13 Janssen Pharmaceutica N.V. BEHANDLUNG VON SYMPTOMEN DER UNTEREN HARNWEGE IM ZUSAMMENHANG MIT BLASENHYPERAKTIVITûT BEI MûNNERN UND FRAUEN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044854A1 (en) * 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69226961D1 (de) 1998-10-15
AU671430B2 (en) 1996-08-29
CA2126354C (en) 2006-07-11
JPH07502528A (ja) 1995-03-16
EP0617620B1 (de) 1998-09-09
WO1993012785A1 (en) 1993-07-08
EP0617620A1 (de) 1994-10-05
DK0617620T3 (da) 1999-06-07
ES2121984T3 (es) 1998-12-16
AU3168393A (en) 1993-07-28
DE69226961T2 (de) 1999-04-29
CA2126354A1 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
DE69226961D1 (de) Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
NO924619D0 (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
MD1616G2 (ro) Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
YU60996A (sh) Inhibitor protein kinaze c, njegove faramceutske formulacije i postupak za dobijanje
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
IL109587A (en) Heparin fractions obtained by nitrous depolymerization, with low nitroso-compound content, method for obtaining them and pharmaceutical compositions containing them
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
ATE166532T1 (de) Anatomisches und biologisches konservierungsmittel und verbesserte einbalsamierungszusammensetzung und -verfahren
KR927003525A (ko) 술폰아닐리드 유도체 및 의약
DK0680323T3 (da) Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DK0391185T3 (da) 1,8-Naphthyridiner
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
AR007020A1 (es) Tratamiento de asma con tnfr-ig
ES2190533T3 (es) Derivados de tropano utilizables en particular para la deteccion in vivo de transportadores de dopamina.
MX9200242A (es) Derivados de piridona triciclicos
ATE314058T1 (de) Verwendung von 5ht3 antagonisten zur fundusentspannung
NO950974L (no) Nye N,N,N',N'-tetrasubstituert-1,2-etandiaminderivatforbindelser
EA199900363A1 (ru) Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee